You are the Medical Communications Lead at a pharmaceutical company preparing to launch a new treatment in the United States and other major markets.
Recent U.S. policy developments involving Most Favored Nation (MFN) prescription drug pricing, which aims to align certain U.S. drug prices with lower prices in comparable countries, have raised questions about how pharmaceutical companies demonstrate treatment value. Although Medical Communications is not responsible for pricing or market access decisions, your Medical Affairs leadership is assessing whether these developments could affect the publication strategy and current publication plan.
Your current publication plan is part of a broader integrated evidence plan developed with Medical Affairs, HEOR, and other evidence-generation colleagues. It emphasizes pivotal clinical trial results, with additional publications planned to address real-world outcomes, disease burden, and evidence gaps. With pivotal clinical publications scheduled around launch and additional evidence publications planned for subsequent months, limited resources mean that accelerating one area of the publication plan would require adjusting timelines or resources for others.
You must recommend which publication priority deserves the greatest attention in this changing environment, while maintaining scientific independence, transparency, and established publication standards.
What Would You Do?
